# Perimenopause: the transition, not the destination

Perimenopause is the 5 to 10 year hormonal transition leading up to menopause, which most women move through roughly between age 40 and 55. Its defining feature in the early phase is hormonal volatility, not a steady decline, so a single blood test in your 40s rarely confirms it; diagnosis is clinical, based on cycle changes and symptoms. Hot flushes and night sweats affect up to about 80 percent of women, and the SWAN cohort found frequent vasomotor symptoms lasted a median of 7.4 years.

Perimenopause is a 5 to 10 year hormonal recalibration that most women move through between roughly age 40 and 55. Here is what the evidence actually says, and what to ignore.

## On this page

- What is perimenopause (and what isn't it)?
- Which symptoms actually show up?
- What changes under the hood?
- Which lifestyle anchors are worth the effort?
- HRT/MHT: what do the guidelines say?
- How do you build a sensible check-up?

## FAQ

- Am I already in perimenopause?
- How long does perimenopause last?
- Is HRT/MHT safe in 2026?
- Should I see a doctor or wait it out?
- Are bioidentical hormones safer than regulated HRT?
- What helps with menopausal sleep disturbance?
- What about weight gain during perimenopause?

## Sources

- Harlow SD, Gass M, Hall JE, Lobo R, Maki P, Rebar RW, Sherman S, Sluss PM, de Villiers TJ. (2012). Executive summary of the Stages of Reproductive Aging Workshop +10: addressing the unfinished agenda of staging reproductive aging. Journal of Clinical Endocrinology & Metabolism. https://doi.org/10.1210/jc.2011-3362
- Manson JE, Aragaki AK, Rossouw JE, Anderson GL, Prentice RL, LaCroix AZ, et al.. (2017). Menopausal hormone therapy and long-term all-cause and cause-specific mortality: the Women's Health Initiative randomized trials. JAMA. https://doi.org/10.1001/jama.2017.11217
- Hodis HN, Mack WJ, Henderson VW, Shoupe D, Budoff MJ, Hwang-Levine J, et al.. (2016). Vascular effects of early versus late postmenopausal treatment with estradiol (ELITE). New England Journal of Medicine. https://doi.org/10.1056/NEJMoa1505241
- The NAMS 2022 Hormone Therapy Position Statement Advisory Panel. (2022). The 2022 Hormone Therapy Position Statement of The North American Menopause Society. Menopause. https://doi.org/10.1097/GME.0000000000002028
- Avis NE, Crawford SL, Greendale G, Bromberger JT, Everson-Rose SA, Gold EB, et al.. (2015). Duration of menopausal vasomotor symptoms over the menopause transition. JAMA Internal Medicine. https://doi.org/10.1001/jamainternmed.2014.8063
- Greendale GA, Huang MH, Wight RG, Seeman T, Luetters C, Avis NE, et al.. (2009). Effects of the menopause transition and hormone use on cognitive performance in midlife women. Neurology. https://doi.org/10.1212/WNL.0b013e3181a71193
- Watson SL, Weeks BK, Weis LJ, Harding AT, Horan SA, Beck BR. (2018). High-intensity resistance and impact training improves bone mineral density and physical function in postmenopausal women with osteopenia and osteoporosis: the LIFTMOR randomized controlled trial. Journal of Bone and Mineral Research. https://doi.org/10.1002/jbmr.3284
- Mosconi L, Berti V, Dyke J, Schelbaum E, Jett S, Loughlin L, et al.. (2021). Menopause impacts human brain structure, connectivity, energy metabolism, and amyloid-beta deposition. Scientific Reports. https://doi.org/10.1038/s41598-021-90084-y
- Chlebowski RT, Anderson GL, Aragaki AK, et al.. (2020). Association of Menopausal Hormone Therapy With Breast Cancer Incidence and Mortality During Long-term Follow-up of the Women's Health Initiative Randomized Clinical Trials. JAMA. https://doi.org/10.1001/jama.2020.9482
- DGGG, OEGGG, SGGG. (2020). S3-Leitlinie 015-062: Peri- und Postmenopause — Diagnostik und Interventionen. https://doi.org/10.1055/a-1361-1948

_Full guide: https://longevity-switzerland.com/en/guide/perimenopause_

---

_Canonical: https://longevity-switzerland.com/en/guide/perimenopause · Part of Longevity Cities · Updated 2026-06-22_